Summary

• Page properties (1 modified, 0 added, 0 removed)

Details

Page properties

Content

...	...	@@ -6,13 +6,11 @@
6	6
7	7	* AstraZeneca is a global, science-led biopharmaceutical business and our innovative medicines are used by millions of patients worldwide.
8	8	* The company  focus on the discovery, development and commercialisation of prescription medicines in Oncology and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology.
9		-* The company also has an active R&D presence in 40 other countries spanning the globe with 0,000 - employees work exclusively in R&D.
	9	+* The company also has an active R&D presence in 40 other countries spanning the globe with 10,000 - employees work exclusively in R&D.
10	10	* Commercial teams of around 43,400 employees are active in more than 100 countries
11	11
12		-
13	13	[[image:AZN0.png||height="175" width="721"]]
14	14
15		-
16	16	= Company Overview =
17	17
18	18	AstraZeneca (LSE:AZN, NASDAQ:AZN) is a global, science-led biopharmaceutical business and its innovative medicines are used by millions of patients worldwide.{{footnote}}https://www.astrazeneca.com/our-company.html{{/footnote}}
...	...	@@ -32,7 +32,6 @@
32	32	* 40 - active R&D presence in other countries spanning the globe
33	33	* 10,000 - employees work exclusively in R&D
34	34
35		-
36	36	The company's pipeline forms a robust portfolio of investigational therapies in varied stages of clinical development.
37	37
38	38	* 175projects in its pipeline
...	...	@@ -39,7 +39,6 @@
39	39	* 17new molecular entities in its late-stage pipeline
40	40	* 1new molecular entity approval
41	41
42		-
43	43	[[image:AZN4.png||alt="AZN2.png"]]
44	44
45	45
...	...	@@ -86,7 +86,6 @@
86	86	* Building expertise and leadership in the most prevalent and highest mortality rate tumour types
87	87	* Delivering across its global footprint
88	88
89		-
90	90	**key disease areas**
91	91
92	92	The company's focus is on some of the most hostile and hard-to-treat cancers. By understanding the complexities of cancer, the company hope to achieve life-changing benefits for patients.
...	...	@@ -241,17 +241,18 @@
241	241
242	242	**Emerging Markets**
243	243
244		-Emerging Markets, as defined in Market definitions on page 280, comprise various countries with dynamic, growing economies. As outlined in Healthcare in a changing world from page 12, these countries represent a major growth opportunity for the pharmaceutical industry due to high unmet medical need and sound economic fundamentals. Emerging Markets are not immune, however, to economic downturn. Market volatility is higher than in Established Markets, and various political and economic challenges exist. These include regulatory and government interventions. In selected markets, governments are encouraging local manufacturing and investment by offering more favourable market access conditions and pricing is increasingly controlled by payers through price referencing regulations in addition to cost effectiveness and cost minimisation approaches.
	239	+Emerging Markets, as defined in Market definitions on page 280, comprise various countries with dynamic, growing economies. As outlined in Healthcare in a changing world from these countries represent a major growth opportunity for the pharmaceutical industry due to high unmet medical need and sound economic fundamentals. Emerging Markets are not immune, however, to economic downturn. Market volatility is higher than in Established Markets, and various political and economic challenges exist. These include regulatory and government interventions. In selected markets, governments are encouraging local manufacturing and investment by offering more favourable market access conditions and pricing is increasingly controlled by payers through price referencing regulations in addition to cost effectiveness and cost minimisation approaches.
245	245
246	246
247	247	Growth drivers for Emerging Markets include new medicines across its Oncology, CVRM and Respiratory & Immunology portfolios. To educate physicians about its broad portfolio, AstraZeneca is selectively investing in sales capabilities where opportunities from unmet medical need exist. AstraZeneca is also expanding its reach through multi-channel marketing and external partnerships.
248	248
249	249
250		-With revenues of $8,711 million (2019: $8,171 million), AstraZeneca was the fourth largest multinational pharmaceutical company, as measured by prescription sales, and the second fastest-growing top 10 multinational pharmaceutical company in Emerging Markets in 2020. Despite the impact of COVID-19 across all geographies the company saw growth across all major areas including Latin America at 0% (18% at CER), Russia & Eurasia at 26% (39% at CER), Middle East & Africa down 4% (up 1% at CER) and Asia Area at 5% (7% at CER).
	245	+With revenues of $8,711 million (2019: $8,171 million), AstraZeneca was the fourth largest multinational pharmaceutical company, as measured by prescription sales, and the second fastest-growing top 10 multinational pharmaceutical company in Emerging Markets in 2020. Despite the impact of COVID-19 across all geographies the company saw growth across all major areas including Latin America at 12% (18% at CER), Russia & Eurasia at 26% (39% at CER), Middle East & Africa down 4% (up 1% at CER) and Asia Area at 5% (7% at CER).
251	251
252	252
253	253	[[image:AZN2.png]]
254	254
	250	+{{putFootnotes/}}
255	255
256	256	= Financial Highlights =
257	257
...	...	@@ -265,7 +265,6 @@
265	265	* Alexion integration progressing well, creating new opportunities in rare diseases
266	266	* Operating Expenses in the quarter reflected the addition of Alexion, as well increased R&D expenses across multiple programs, investment in its COVID-19 medicines, and increased SG&A from pre-launch activities following successful pipeline delivery
267	267
268		-
269	269	**Pascal Soriot, Chief Executive Officer, commented:**
270	270
271	271	AstraZeneca’s scientific leadership continues to provide strong revenue growth and exceptional pipeline delivery, with eight positive late-stage readouts across seven medicines since June, including its long acting antibody combination showing promise in both prevention and treatment of COVID-19. The addition of Alexion furthers its commitment to bring transformative therapies to patients around the world, and I am proud of its colleagues’ ongoing dedication and focus.
...	...	@@ -284,7 +284,6 @@
284	284	* In the US, Total Revenue increased by 29% to $8,305m and in Europe by 40% (31% at CER) to $5,178m, including pandemic COVID-19 vaccine revenue of $736m
285	285	* Growth in Core EPS13 to $5.05 to $5.40, in line with prior guidance.
286	286
287		-
288	288	Oncology Total Revenue of $9,744m in the year to date; an increase of 19% (16% at CER). Oncology represented 38% of overall Total Revenue (YTD 2020: 43%).
289	289
290	290